lirilumab lirilumab lirilumab (inn) is a human monoclonal antibody designed for the treatment of cancer. it binds to kir2dl1/2l3. lirilumabmonoclonal antibodytypewhole antibodysourcehumantargetkir2dl1/2/3clinical dataatc codenoneidentifierscas number1000676-41-4chemspidernoneuniis9xdi9w918keggd10444chemical and physical dataformulac6452h9918n1698o2030s46molar mass145228.93 g·mol−1 this drug was developed by innate pharma and is licensed to bristol-myers squibb. clinical trials a phase 2 clinical trial for acute myeloid leukemia (aml) was terminated early ("failed") in 2017. it was registered for a trial for squamous cell carcinoma of the head and neck (scchn), but it may be abandoned. as of november 2017 nine clinical trials of lirilumab are registered as active.